Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients

Medical Science Monitor

Volumn 14, Issue 11, 2008, Pages

  Nagao, Yumiko ^a   Kawakami, Yutaka ^b   Yoshiyama, Tamotsu ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PFIZER INC   (United States)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Interferon therapy; Liver specialist; Non liver specialist

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT ATTITUDE; RISK FACTOR; STRUCTURED QUESTIONNAIRE; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 55549140170     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001; 94: 153-56
2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999; 340: 745-50
3. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology, 2002; 62 (Suppl.1): 8-17
4. Okita K: Clinical study on standardization of treatment of carriers of hepatitis B and C viruses; the current status of hepatitis virus screening and future problems of guidance for patients who require thorough examination. Research on Hepatitis. Health and Labour Sciences Research Grants, Ministry of Health, Labour, and Welfare, Japan, 2007; 204-7 (in Japanese)
5. Muir AJ, Bornstein JD, Killenberg PG: Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med, 2004; 350: 2265-71
6. Yoshida H, Shiratori Y, Moriyama M et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med, 1999; 131: 174-81
7. Yoshida H, Arakawa Y, Sata M et al: Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology, 2002; 123: 483-91
8. Okanoue T, Itoh Y, Minami M et al: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol, 1999; 30: 653-59
9. Mazzaferro V, Romito R, Schiavo M et al: HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology, 2006; 44: 1543-54
10. Nagao Y, Sata M, Suzuki F et al: Toward more widespread use of novel drug therapies -Current status of interferon therapy in patients with hepatitis C and discussion of strategies to propagate its use. Office of Pharmaceutical Industry Research. Research Paper Series, 2006; 32: 1-81 (in Japanese)
11. Sata M, Nakano H, Suzuki H et al: Sero-epidemiologic study of hepatitis C virus infection in Fukuoka, Japan. J Gastroenterol, 1998; 33: 218-22
12. Fukuizumi K, Sata M, Suzuki H et al: Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study. Scand J Infect Dis, 1997; 29: 345-47
13. Nagao Y, Fukuizumi K, Kumashiro R et al: The prognosis for life in an HCV hyperendemic area. Gastroenterology, 2003; 125: 628-29
14. Nagao Y, Tanaka K, Kobayashi K et al: A cohort study of chronic liver disease in an HCV hyperendemic area of Japan: a prospective analysis for 12 years. Int J Mol Med, 2004; 13: 257-65
15. Nagao Y, Tanaka K, Kobayashi K et al: Analysis of approach to therapy for chronic liver disease in an HCV hyperendemic area of Japan. Hepatol Res, 2004; 28: 30-35
16. Nagao Y, Sata M, Fukuizumi K et al: High incidence of oral precancerous lesions in a hyperendemic area of hepatitis C virus infection. Hepatol Res, 1997; 8: 173-77
17. Nagao Y, Sata M, Fukuizumi K et al: High incidence of oral lichen planus in an HCV hyperendemic area. Gastroenterology, 2000; 119: 882-83
18. nd ed. New York: John Wiley & Sons; 2000; 91-116
19. Ohishi W, Kitamoto M, Aikata H et al: Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol, 2003; 38: 894-900
20. Hayashi J, Kishihara Y, Ueno K et al: Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med, 1998; 158: 177-81
21. Hung CH, Lee CM, Lu SN et al: Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int, 2006; 26: 1079-86